Education
About Us
Working with TipRanks
Follow Us
Nuvalent (NUVL)
NASDAQ:NUVL
NUVL Stock Chart & Stats
Day’s Range― - ―
52-Week Range$55.54 - $113.51
Previous CloseN/A
Volume65.93K
Average Volume (3M)479.02K
Market Cap
$5.74B
Enterprise Value$4.48B
Total Cash (Recent Filing)$1.01B
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.24
Next Earnings
Nov 06, 2025EPS Estimate
-1.36Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.39
Shares Outstanding66,669,586
10 Day Avg. Volume421,240
30 Day Avg. Volume479,016
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap0.78
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-12.36
Forecast
1Y Price Target
$115.60Price Target Upside42.91% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
Bulls Say, Bears Say
Bulls Say
Earnings PotentialNuvalent is seen as one of the few biotech companies that can realistically generate new multi-billion-dollar drug sales from lung cancer.
Product LaunchThe upcoming ROS1 and TKI pre-treated ALK commercial launches are anticipated to have significant sales potential.
Regulatory ProgressThe rolling NDA submission for zidesamtinib has initiated and is expected to be part of the FDA's Real-Time Oncology Review pilot program, which facilitates earlier submission of topline efficacy and safety results.
Bears Say
Clinical Data RisksDownside risks include timeline setbacks for upcoming read-outs and underwhelming clinical data.
Enrollment ChallengesSome investors are nervous about potentially lengthy enrollment/data timelines for the 1L trial given the number of patients required and the PFS associated with alectinib.
Nuvalent News
NUVL FAQ
What was Nuvalent’s price range in the past 12 months?
Nuvalent lowest stock price was $55.53 and its highest was $113.51 in the past 12 months.
What is Nuvalent’s market cap?
Nuvalent’s market cap is $5.74B.
When is Nuvalent’s upcoming earnings report date?
Nuvalent’s upcoming earnings report date is Nov 06, 2025 which is in 60 days.
How were Nuvalent’s earnings last quarter?
Nuvalent released its earnings results on Aug 07, 2025. The company reported -$1.39 earnings per share for the quarter, missing the consensus estimate of -$1.225 by -$0.165.
Is Nuvalent overvalued?
According to Wall Street analysts Nuvalent’s price is currently Undervalued.
Does Nuvalent pay dividends?
Nuvalent does not currently pay dividends.
What is Nuvalent’s EPS estimate?
Nuvalent’s EPS estimate is -1.36.
How many shares outstanding does Nuvalent have?
Nuvalent has 66,669,586 shares outstanding.
What happened to Nuvalent’s price movement after its last earnings report?
Nuvalent reported an EPS of -$1.39 in its last earnings report, missing expectations of -$1.225. Following the earnings report the stock price went down -6.565%.
Which hedge fund is a major shareholder of Nuvalent?
Currently, no hedge funds are holding shares in NUVL
Nuvalent Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$115.60 (42.91% Upside)
$115.60 (42.91% Upside)
Blogger Sentiment
Bullish
NUVL Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 737.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-5.80%
12-Months-Change
Fundamentals
Return on Equity
-43.55%
Trailing 12-Months
Asset Growth
54.10%
Trailing 12-Months
Company Description
Nuvalent
Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.
NUVL Stock 12 Month Forecast
Average Price Target
$115.60
▲(42.91% Upside)
Technical Analysis
Blueprint Medicines
―
Axsome Therapeutics
―
Verona Pharma
―
Krystal Biotech
―
Revolution Medicines
―
Ownership Overview
32.64% Insiders
22.93% Mutual Funds
<0.01% Other Institutional Investors
33.07% Public Companies and
Individual Investors